An immune-active tumor microenvironment favors clinical response to ipilimumab
Rui‐Ru Ji, Scott D. Chasalow, Lisu Wang et al. · Cancer Immunology Immunotherapy · 2011
Cited by 775 works. doi:10.1007/s00262-011-1172-6
Authors
- Rui‐Ru Ji
- Scott D. Chasalow
- Lisu Wang
- Omid Hamid
- Henrik Schmidt
- John P. Cogswell
- Suresh Alaparthy
- Maria Jure‐Kunkel
- Nathan O. Siemers
- Jeffrey R. Jackson
- Vafa Shahabi
References
- Nonparametric Estimation from Incomplete Observations
- Nonparametric Estimation from Incomplete Observations
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- 1969 Cancer Facts and Figures
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
- High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993
- CTLA-4-Mediated Inhibition in Regulation of T Cell Responses: Mechanisms and Manipulation in Tumor Immunotherapy
- Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients